FGA to SGA Depot Switch — MRCPsych Paper B MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Switch to an SGA long-acting injectable selected jointly for a more favourable EPS profile
The correct answer is D. The temporal relationship, symmetrical rigidity, bradykinesia and tremor indicate antipsychotic-induced parkinsonism. It remains disabling despite dose reduction, while an LAI remains clinically important because oral non-adherence previously caused relapse. NICE recommends individualised antipsychotic selection that explicitly considers extrapyramidal adverse effects; switching to an SGA LAI with a more favourable EPS profile is therefore appropriate. This is not a class-wide guarantee: paliperidone can cause EPS, and aripiprazole can cause akathisia, so the specific drug requires shared risk-benefit assessment. Increasing the FGA dose is likely to worsen EPS. Long-term high-dose procyclidine adds anticholinergic burden and does not address the cause. Accepting disabling EPS is inappropriate, while abrupt cessation without replacement creates substantial relapse risk.
Reference: NICE. Psychosis and schizophrenia in adults: prevention and management (CG178), recommendations 1.3.5.1, 1.3.6.3 and 1.5.6.1. 2014, current online version. https://www.nice.org.uk/Guidance/CG178/chapter/recommendations